Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer


A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer


Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery.


This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating women with non-metastatic breast cancer.

Study Status: Active, not recruiting


Condition Intervention Phase
Breast Cancer Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Paclitaxel
Phase 3

Verified by National Surgical Adjuvant Breast and Bowel Project (NSABP) December, 2013

Sponsored by: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Information provided by: National Surgical Adjuvant Breast and Bowel Project (NSABP) identifier: NCT01547741

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Cancer Center Beachwood
Beachwood, Ohio 44122
United States

Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio 44111
United States

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Cleveland Clinic Cancer Center Independence
Independence, Ohio 44131
United States

Cleveland Clinic Cancer Center-Strongsville
Strongsville, Ohio 44136
United States

Cleveland Clinic Wooster Specialty Center
Wooster, Ohio 44691
United States

Norman Wolmark, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site